替米沙坦对原发性高血压患者血管内皮功能的保护作用

目的探讨替米沙坦对原发性高血压患者血管内皮功能的保护作用。方法选择50例原发性高血压患者（治疗组）予以口服替米沙坦胶囊（40～80）mg／d，连用12周；另选我院体检中心健康体检者30例作为对照组。结果治疗组患者予以替米沙坦治疗12周后，收缩压和舒张压均下降至正常（P〈0．05或P〈0．01）。治疗组患者治疗前血浆VEGF、ET-1和vWF水平较对照组明显升高，而血浆NO水平较对照组明显降低（均P〈0．01）；予以替米沙坦治疗12周后，患者血浆VEGF、ET-1和vwF水平明显下降，而血浆NO水平明显上升（均P〈0．01）。结论替米沙坦具有良好的降压作用，能明显改善并保护患者血管内皮功能。

The Protection of Telmisartan for the Function of Vascular Endothelium of Patients with Essential Hypertension

Objective To explore the protection of telmisartan for the function of vascular endothelium for patients with essential hypertension. Methods Fifty patients with essential hypertension were set as therapy group, took the telmisartan orally （ 40 - 80 ） rag/ d for 12 weeks. Another 30 healthy people were chose as control group. Results After 12 weeks treated by telmisartan, the systolic and diatolic pressures of the patients in the therapy control were well controlled （ P 〈 0.05 or P 〈 0.01 ）. Before the treatment, the plasma level of VEGF, ET-land vWF of patients of therapy group were significantly higher than that of control group, while the NO was oppsite （P 〈 0.01 ）. After 12 weeks treatment by telmisartan, the level of VEGF, ET-1 and vWF of paitents of therapy group decreased significantly, and the level of NO rising significantly （ P 〈 0.01 ）. Conclusion Telmisartan can well descend the blood pressure, improve and protect the function of the vascular endothelium of the patients.